(Total Views: 641)
Posted On: 11/19/2021 8:35:14 AM
Post# of 153395
From the Frontiers paper: "Using these assays, we
found that Leronlimab stabilized cell surface CCR5, leading to an increase in the levels of
circulating and tissue-resident CCR5+CD4+ T cells in vivo in Leronlimab-treated
macaques. Weekly Leronlimab treatment in a chronically SIV-infected macaque led to
increased CCR5+CD4+ T cells levels and fully suppressed plasma viremia, both
concomitant with full CCR5 RO on peripheral blood CD4+ T cells, demonstrating that
CCR5+CD4+ T cells were protected from viral replication by Leronlimab binding." Powerful stuff!
found that Leronlimab stabilized cell surface CCR5, leading to an increase in the levels of
circulating and tissue-resident CCR5+CD4+ T cells in vivo in Leronlimab-treated
macaques. Weekly Leronlimab treatment in a chronically SIV-infected macaque led to
increased CCR5+CD4+ T cells levels and fully suppressed plasma viremia, both
concomitant with full CCR5 RO on peripheral blood CD4+ T cells, demonstrating that
CCR5+CD4+ T cells were protected from viral replication by Leronlimab binding." Powerful stuff!
(6)
(0)Scroll down for more posts ▼
